Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT00862082 | Terminated Phase 1 Results

• 1 other identifier: PR104-2002
• Study Type: interventional
• Target: 14
• Locations: 4 countries
• Sites: 17

Brief Summary

The current understanding of PR104 justifies the evaluation of PR104 with sorafenib in patients with hepatocellular carcinoma. These include:

• Hypoxia. Hepatocellular Carcinoma (HCC) is likely to demonstrate a level of hypoxia sufficient to activate PR104 to its active metabolites PR104H and PR104M. In addition, in preclinical models, sorafenib has been demonstrated to increase the degree of hypoxia in tumors following treatment.
• Non-overlapping toxicity. PR104 and sorafenib do not share major toxicities. It is anticipated that both drugs can be administered at their full single agent dose when used in combination.
• Aldo-keto reductase 1C3 (AKR1C3). HCC has been shown to express high levels of AKR1C3 which should lead to selective activation of PR104 within both hypoxic and oxic HCC cells.
• Preclinical data. The use of sorafenib and PR104 alone and in combination in a hepatocellular carcinoma model demonstrates activity of PR104 as a single agent and increased activity when PR104 and sorafenib are used in combination. The current study will provide an estimate of the activity of PR104 in subjects with HCC. This information will prove valuable in defining the future clinical development of PR104, and in determining if PR104 has sufficient activity in HCC to warrant a larger phase III registration study in this indication. Primary objectives
• Phase I: Determine the maximum tolerated dose (MTD) of PR104 when used in combination with standard dose sorafenib
• Phase II: Estimate the response rate (RR) of PR104/sorafenib \[Note: Phase II was never initiated\] Secondary objectives
• Evaluate survival
• Evaluate Progression Free Survival (PFS)
• Evaluate time to progression (TTP)
• Evaluate safety
• Evaluate the pharmacokinetics (PK) of sorafenib, PR104 and PR104 metabolites
• Collect diagnostic biopsy samples for the determination of aldo-keto reductase 1C3
• Collect plasma samples for assessment of potential biomarkers of tumor hypoxia

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

• Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population

  4 weeks (1 cycle)

Secondary Outcomes (7)

• Safety and Tolerability: Serious Adverse Events

  30 days following the last administration of study treatment

• Pharmacokinetics [Maximum Plasma Concentration (Cmax)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)

  Day 1 of Cycles 1 and 2

• Pharmacokinetics [Half Life (T1/2)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)

  Day 1 of Cycles 1 and 2

• Pharmacokinetics [Area Under the Curve(AUC)] of PR104 and PR104 Metabolites in Cohort 1 (770 mg/m^2 Dose Group)

  Day 1 of Cycles 1 and 2

• Pharmacokinetics (Cmax) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)

  Day 1 of Cycles 1 and 2

Study Arms (1)

PR104 + Sorafenib

EXPERIMENTAL

PR104 will be administered IV once every four weeks, in addition to 400mg sorafenib PO twice daily

Drug: PR104 550 mg/m^2 + sorafenib; Drug: PR104 770 mg/m^2 + sorafenib

Interventions

PR104 550 mg/m^2 + sorafenib DRUG

550 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.

Also known as: PR-104, Nexavar

PR104 + Sorafenib

PR104 770 mg/m^2 + sorafenib DRUG

770 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.

Also known as: PR-104, Nexavar

PR104 + Sorafenib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Advanced-stage hepatocellular carcinoma considered non-operable that is suitable for treatment with sorafenib. Subjects who have demonstrated progression following initial surgical or locoregional therapy are eligible
• Confirmed hepatocellular carcinoma by pathological analysis (tissue aspirate or biopsy)
• No previous systemic therapy for hepatocellular carcinoma
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Child-Pugh liver function class A
• Life expectancy of 12 weeks or more
• Adequate hematologic function \[Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L; platelet count ≥100×10\^9 per liter; hemoglobin ≥8.5 g per deciliter maintained in the absence of red blood cell transfusions; and prothrombin time international normalized ratio ≤1.7; or prothrombin time ≤2 seconds above control\]
• Adequate hepatic function (albumin ≥2.8 g per deciliter; total bilirubin ≤2 mg per deciliter \[51.3 μmol per liter\]; and alanine aminotransferase and aspartate aminotransferase ≤5 times the upper limit of the normal range)
• Adequate renal function (serum creatinine ≤1.5 times the upper limit of the normal range or creatinine clearance ≥60 mL/min).
• At least one untreated target lesion that could be measured in one dimension, according to the Response Evaluation Criteria in Solid Tumors (RECIST)
• Concomitant systemic antiviral therapy allowed

You may not qualify if:

• Previous molecularly targeted therapies or any other systemic treatment for hepatocellular carcinoma
• Active concomitant malignancy likely to effect any of the primary or secondary outcome measures in the current study
• Women who are pregnant, breast-feeding or planning to become pregnant during the study
• Men or women of reproductive-potential who are unwilling to use an effective method of contraception during the study and for 30 days following the last dose of study medication
• Evidence of a significant medical disorder or laboratory finding that, in the opinion of the Investigator, compromises the subject's safety during study participation such as: uncontrolled infection or infection requiring a concomitant parenteral antibiotic; uncontrolled diabetes; congestive heart failure; myocardial infarction within 6 months of study; chronic renal disease; or coagulopathy (excluding prophylactic anticoagulation)
• Active central nervous system metastatic disease requiring intervention
• Less than four weeks since major surgery
• Known Human Immunodeficiency Virus (HIV) positivity

Sponsors & Collaborators

• Proacta, Incorporated: lead

Study Sites (17)

University of Arizona

Tucson, Arizona, 85724, United States

Location

Moores UCSD Cancer Center

La Jolla, California, 92093, United States

Location

University of California, Irvine

Orange, California, 92868, United States

Location

Sharp Clinical Oncology Research

San Diego, California, 92123, United States

Location

Pacific Oncology/Hematology

San Francisco, California, 94115, United States

Location

Northwestern University

Chicago, Illinois, 60611, United States

Location

Indiana University Simon Cancer Center

Indianapolis, Indiana, 46202, United States

Location

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

Baltimore, Maryland, 21231, United States

Location

Columbia University Medical Center

New York, New York, 10032, United States

Location

Prince of Wales Hospital

Shatin, New Territories, Hong Kong

Location

Singapore General Hospital

Singapore, Singapore

Location

Chang Gung Memorial Hospital

Kaohsiung City, Taiwan

Location

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, Taiwan

Location

China Medical University Hospital

Taichung, Taiwan

Location

Chi Mei Medical Center, Liouying

Tainan, Taiwan

Location

Cathay General Hospital

Taipei, 10630, Taiwan

Location

National Taiwan University Hospital

Taipei, Taiwan

Location

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Interventions

PR-104; Sorafenib

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Intervention Hierarchy (Ancestors)

Phenylurea Compounds; Urea; Amides; Organic Chemicals; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Niacinamide; Nicotinic Acids; Acids, Heterocyclic; Heterocyclic Compounds; Pyridines; Heterocyclic Compounds, 1-Ring

Limitations and Caveats

Early termination leading to small numbers of subjects analyzed. Phase II part of study never initiated.

Results Point of Contact

• Title: Director of Clinical Development
• Organization: Proacta, Inc.

clinicalops@proacta.com

858-642-0386

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 12, 2009
• First Posted: March 16, 2009
• Study Start: March 1, 2009
• Primary Completion: January 1, 2010
• Study Completion: May 1, 2010
• Last Updated: August 23, 2013
• Results First Posted: August 23, 2013

Record last verified: 2013-07

Locations

TW (6); US (9); HK (1); SG (1)